Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">AveXis presents results from the closeout of the Phase 1 trial of AVXS-101 in spinal muscular atrophy Type 1 at the AAN Annual Meeting (81.32 +2.14)<p>Douglas Sproule, MD, Vice President of Clinical Development, and Medical Affairs of AveXis, presented, «AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Experience with Preexisting Anti-AAV9 Antibody in the SMA1 Population,» results of which suggest pre-existing antibodies to AAV9 are quite uncommon in the pediatric population and will not impact use of gene therapy for the vast majority of SMA Type 1 patients.</p><ul><li>Two patients in the Phase 1 study who had modestly elevated anti-AAV9 titers, presumably resulting from maternal antibody transfer through breastfeeding or placental-transfer, showed resolution at retesting that enabled dosing.</li><li>Co will host a conference call and webcast at 4:30 p.m. ET today, April 25, to discuss these data.</li></ul></td> </tr></table>"